Syntrix Biosystems

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Syntrix Biosystems sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

Syntrix Biosystems: 9 sponsored US clinical trials, 2 recruiting.

Syntrix Biosystems sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma Stage IV, with 1 trials.

Top-decile sponsor footprint

Syntrix Biosystems ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

NCT06228053
RECRUITING Phase 1

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

NCT04245397
ACTIVE NOT RECRUITING Phase 1

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431
COMPLETED Phase 1

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

NCT04683926
COMPLETED Phase 2

Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

NCT03664921
COMPLETED Phase 2

Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis

NCT03431974
COMPLETED Phase 1

Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers

NCT03312777
COMPLETED Phase 1

Omnitram Pharmacokinetic Study In Healthy Volunteers

NCT02205554
COMPLETED Phase 1

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

NCT00937027

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3

Therapeutic Areas

Melanoma Stage IV 1
Melanoma Stage III 1
Pain 1
Myelodysplastic Syndromes 1
Metastatic Castration-Resistant Prostate Cancer 1

What is open in the Syntrix Biosystems pipeline

2 recruiting of 9 indexed (22% open); 6 completed (67%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Melanoma Stage IV (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Syntrix Biosystems: open-pipeline peers nationwide

Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.

Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8101214161820 0%10%20%30%40%50% Total trials Recruiting share Syntrix Biosystems4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyALX OncologyBiosense WebsterEnglewood Hospital and Medical CenterEnsysce Biosciences
Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Syntrix Biosystems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 22% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Syntrix Biosystems page

9 registered trials is a research-attention snapshot, not an endorsement of Syntrix Biosystems or any single study.

  • 2 of Syntrix Biosystems's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Melanoma Stage IV is the condition Syntrix Biosystems studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma Stage IV trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Syntrix Biosystems pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.